Oral Session 2-8C DLBCL: Treatment

[OS2-8C-2] DA-EPOCH-R with high-dose methotrexate (HD-MTX) for CD5+ DLBCL: Primary analysis of PEARL5 study

Kana Miyazaki¹, Naoko Asano², Tomomi Yamada³, Kohta Miyawaki⁴, Hirotaka Takasaki⁵, Tadahiko Igarashi⁶, Momoko Nishikori⁷, Kinya Ohata⁸, Kazutaka Sunami⁹, Isao Yoshida¹⁰, Go Yamamoto¹¹, Naoki Takahashi¹², Masataka Okamoto¹³, Hiroki Yano¹⁴, Yuki Nishimura¹⁵, Satoshi Tamaru¹⁵, Masakatsu Nishikawa¹⁵, Koji Izutsu^11,16, Tomohiro Kinoshita¹⁷, Junji Suzumiya¹⁸, Koichi Ohshima¹⁹, Koji Kato⁴, Naoyuki Katayama¹, Motoko Yamaguchi¹ (1.Department of Hematology and Oncology, Mie University, Tsu, Japan, 2.Nagano Prefectural Shinshu Medical Center, Suzaka, Japan, 3.Osaka University Hospital, Suita, Japan, 4.Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, 5.Kanagawa Cancer Center, Yokohama, Japan, 6.Gunma Cancer Center, Ohta, Japan, 7.Kyoto University, Kyoto, Japan, 8.Kanazawa University, Kanazawa, Japan, 9.Okayama Medical Center, Okayama, Japan, 10.Shikoku Cancer Center, Matsuyama, Japan, 11.Toranomon Hospital, Tokyo, Japan, 12.International Medical Center, Saitama Medical University, Hidaka, Japan, 13.Fujita Health University, Toyoake, Japan, 14.Kainan Hospital, Yatomi, Japan, 15.Mie University Hospital, Tsu, Japan, 16.National Cancer Center Hospital, Tokyo, Japan, 17.Aichi Cancer Center Hospital, Nagoya, Japan, 18.Shimane University Hospital, Izumo, Japan, 19.Kurume University, Kurume, Japan)